Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia | Disease Landscape & Forecast | G7 | 2023
The launch of several novel therapies and multiple label expansions for premium-priced agents will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) / chronic lymphocytic leukemia (CLL) therapy market. Key therapies that we expect to fuel growth are the CAR T-cell therapies Yescarta (Gilead), Kymriah (Novartis), Tecartus (Gilead), and Breyanzi (Bristol Myers Squibb) as well as the targeted agents Polivy (Roche), Monjuvi / Minjuvi (MorphoSys / Incyte), Tazverik (Epizyme), Brukinsa (BeiGene), and Zynlonta (ADC Therapeutics); also, approval of bispecific antibodies Lunsumio (Roche), Epkinly / Tepkinly (Genmab / AbbVie), and Columvi (Roche) will drive growth. We also expect the noncovalent BTK inhibitor Jaypirca (Loxo Oncology / Eli Lilly) for CLL / SLL and combinations incorporating Imbruvica (Janssen / AbbVie), Calquence (AstraZeneca), and Venclexta / Venclyxto (AbbVie / Roche) to enter the CLL market, causing a shift away from conventional immunochemotherapy regimens. Notably, the anticipated launch of other bispecific antibody—odronextamab (Regeneron Pharmaceuticals), antibody-drug conjugate brentuximab vedotin (Seagen) etc. will further fragment the FL, CLL / SLL, DLBCL, and MCL patient settings, creating intense competition.
Questions Answered
- What is the size of clinically and commercially relevant drug-treatable NHL / CLL populations, and how will drug-treatment rates change over the 2022-2032 forecast period, by geography?
- What is the market impact of label expansions of CAR T-cell therapies in earlier lines of R/R DLBCL? What is the expected market impact of other drug approvals in various NHL / CLL patient populations?
- Which emerging therapies are the most promising in NHL / CLL, and what patient populations will they target?
- What factors are driving growth in the NHL / CLL market? Which drug class will dominate the treatment of NHL / CLL?
Content Highlights
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 19 country-specific interviews with experts and 210 country-specific surveys with hematologist-oncologists treating NHL.
Epidemiology: Diagnosed incidence of NHL by country; drug-treatable and drug-treated cases segmented by subtype (follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia / small lymphocytic leukemia) and line of therapy.
Population segments in market forecast: First-line, second-line, third-line, and fourth-line for FL, CLL / SLL, DLBCL, and MCL.
Emerging therapies: Phase III / PR: 4+ drugs.
Product Description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution Enhancement
Disease Landscape & Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
